Augmenting interferon-β and anti-PD-L1 antibody bolsters non-ablative radiotherapy to leverage potent abscopal effect in metastatic cancers.

Park JH, Kim HY, Choi J, Kim HJ, Ahn KJ, Park ET, Byun KD, Kim JI, Kim TH, Kim IH, Park S.

Open source

DOI: 10.3389/fimmu.2026.1925859
Published: 2026-09-01
Container: Front Immunol
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fimmu.2026.1925859,
  title = {Augmenting interferon-β and anti-PD-L1 antibody bolsters non-ablative radiotherapy to leverage potent abscopal effect in metastatic cancers.},
  author = {Park JH and  Kim HY and  Choi J and  Kim HJ and  Ahn KJ and  Park ET and  Byun KD and  Kim JI and  Kim TH and  Kim IH and  Park S.},
  year = {2026},
  journal = {Front Immunol},
  doi = {10.3389/fimmu.2026.1925859},
  url = {https://doi.org/10.3389/fimmu.2026.1925859}
}

RIS

TY  - JOUR
TI  - Augmenting interferon-β and anti-PD-L1 antibody bolsters non-ablative radiotherapy to leverage potent abscopal effect in metastatic cancers.
AU  - Park JH
AU  -  Kim HY
AU  -  Choi J
AU  -  Kim HJ
AU  -  Ahn KJ
AU  -  Park ET
AU  -  Byun KD
AU  -  Kim JI
AU  -  Kim TH
AU  -  Kim IH
AU  -  Park S.
PY  - 2026
JO  - Front Immunol
DO  - 10.3389/fimmu.2026.1925859
UR  - https://doi.org/10.3389/fimmu.2026.1925859
ER  -

APA

JH, P., HY, K., J, C., HJ, K., KJ, A., ET, P., KD, B., JI, K., TH, K., IH, K., & S., P. (2026). Augmenting interferon-β and anti-PD-L1 antibody bolsters non-ablative radiotherapy to leverage potent abscopal effect in metastatic cancers.. Front Immunol. https://doi.org/10.3389/fimmu.2026.1925859

Source records

europe-pmc · retrieved 2026-09-25T19:38:44.801Z
doaj · retrieved 2026-09-25T19:38:44.798Z